688221.SHG Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A

Healthcare Biotechnology Shanghai Stock Exchange
12.94 CNY
Close of Nov 4, 2026
12.09 29.98
Market cap
CNY 4.85B
P/E
-
P/B
4.45x
ROE
28.8%
Dividend yield
0.17%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 688221.SHG undervalued?

Graham number

The Graham number of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A fundamental analysis

No fundamental analysis for Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A yet.

Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company's pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 …

Full company profile